Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corteva (CTVA) Cash & Equivalents (2018 - 2025)

Corteva (CTVA) has 8 years of Cash & Equivalents data on record, last reported at $4.5 billion in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 45.56% year-over-year to $4.5 billion; the TTM value through Dec 2025 reached $4.5 billion, up 45.56%, while the annual FY2025 figure was $4.5 billion, 45.56% up from the prior year.
  • Cash & Equivalents reached $4.5 billion in Q4 2025 per CTVA's latest filing, up from $2.5 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $4.5 billion in Q4 2025 and bottomed at $1.5 billion in Q1 2024.
  • Average Cash & Equivalents over 5 years is $2.6 billion, with a median of $2.4 billion recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: decreased 28.44% in 2022, then surged 45.56% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $4.5 billion in 2021, then fell by 28.44% to $3.2 billion in 2022, then decreased by 17.14% to $2.6 billion in 2023, then increased by 17.47% to $3.1 billion in 2024, then surged by 45.56% to $4.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $4.5 billion in Q4 2025, $2.5 billion in Q3 2025, and $2.1 billion in Q2 2025.